Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 30, 2020

            Details:

            The trials come after a Chinese official told reporters last month that an active ingredient of the drug had been effective, with no obvious side effects, in helping coronavirus patients recover.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recombinant triple antigen vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 30, 2020

            Details:

            Premas Biotech has adopted a three-pronged approach to develop multi subunit vaccine, using recombinantly expressed antigens Spike, Envelope, and Membrane proteins in multiple formats.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DNA Vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: The Department of Biotechnology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding April 20, 2020

            Details:

            Funding to support Cadila Healthcare for advancing its DNA Vaccine candidate against SARS-CoV-2 and to Bharat Biotech for COVID-19 vaccine candidate utilising the inactivated rabies vector platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Interferon alpha-2b

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 20, 2020

            Details:

            Interferon alpha can potentially emerge as one of the treatment options for COVID 19; In vitro and in vivo studies suggest positive effects on COVID-19 Patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Active virosome vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: The Union science and technology ministry of India

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding April 12, 2020

            Details:

            The Union science and technology ministry will fund Seagull Biosolutions to develop a vaccine for Covid-19 which is expected to enter phase-1 trial in 18-20 months.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 26, 2020

            Details:

            Vopec Pharmaceuticals has received the NOC and license to develop and test its new anti cancer drug as a new chemical entity (NCE), which also offers a promising therapeutic option for COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Coronvirus vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Akers Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 24, 2020

            Details:

            Akers will in-license a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform and partner with Premas to seek FDA approval.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DNA vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 17, 2020

            Details:

            Adopting a two-pronged approach, a DNA based vaccine and a live attenuated recombinant measles virus vectored vaccine to combat the virus.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Live-attenuated vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Codagenix

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 14, 2020

            Details:

            Codagenix has designed multiple nCoV vaccine candidate genomes using its proprietary deoptimization technology. The vaccine viruses will then be grown and tested in vivo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lopinavir,Ritonavir

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            Lopinavir and ritonavir - are the protease inhibitors that are designed to block HIV viral replication and are now being repurposed to deal with coronavirus.